(Total Views: 462)
Posted On: 10/14/2021 11:04:53 AM
Post# of 155706
Fortuno,
It is my understanding that Cytodyn is forever “running on fumes”. That goes with being a pre-revenue biotech.
Cytodyn has an obligation to confront Amarex for failure to fulfill the tasks for which it has been paid. We would be castigating NP as covering for Amarex had Amarex not been held accountable.
Cytodyn remains a tiny company with many headwinds. I don’t blame any for choosing to invest elsewhere, but divorcing Amarex is not the catalyst that IMO should compel divestiture.
It is my understanding that Cytodyn is forever “running on fumes”. That goes with being a pre-revenue biotech.
Cytodyn has an obligation to confront Amarex for failure to fulfill the tasks for which it has been paid. We would be castigating NP as covering for Amarex had Amarex not been held accountable.
Cytodyn remains a tiny company with many headwinds. I don’t blame any for choosing to invest elsewhere, but divorcing Amarex is not the catalyst that IMO should compel divestiture.
(10)
(0)
